Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Showing 1 to 6 of 6 results for casirivimab and imdevimab

  1. COVID-19 rapid guideline: managing COVID-19 (NG191)

    This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.

    COVID-19 rapid guideline
    Last updated
    1 May 2025

    Sections for NG191

  2. What is the effectiveness, cost effectiveness and safety of using a combination of casirivimab and imdevimab at doses other than 8 g for treating COVID-19?

    effectiveness, cost effectiveness and safety of using a combination of casirivimab and imdevimab at doses other than 8 g for treating...

    Research recommendation
    Published
    12 November 2021

  3. What is the effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical characteristics (for example, people who are seropositive, of unknown serostatus, immunocompromised, or with specific comorbidities and within both the seropositive and seronegative groups, according to vaccination status or history of natural infection)?

    effectiveness, cost effectiveness and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with...

    Research recommendation
    Published
    21 October 2021

  4. What is the effectiveness and safety of neutralising monoclonal antibodies against different SARS-CoV-2 variants?

    immunocompromised I: neutralising monoclonal antibodies combination of casirivimab and imdevimab sotrovimab any neutralising monoclonal...

    Research recommendation
    Published
    9 March 2022

  5. Tixagevimab plus cilgavimab for preventing COVID-19 (TA900)

    Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.

    Technology appraisal guidance
    Published
    14 June 2023
    View recommendations

    Sections for TA900

  6. 3 treatments for COVID-19 recommended in draft guidance

    Three treatments for COVID have been recommended in draft NICE guidance released today for public consultation.

    News
    Last updated
    26 January 2024